

**U.S. FDA APPROVES ANTIEMETIC AGENT AKYNZEO® FOR PREVENTION OF  
CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV)**

*World's First Oral Fixed Combination Targeting Two Critical Pathways Involved in CINV*

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that Helsinn Healthcare S.A. (Headquarters: Lugano, Switzerland, CEO: Riccardo Braglia, "Helsinn") has received approval from the U.S. Food and Drug Administration (FDA) for AKYNZEO® (generic name: netupitant/palonosetron), indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including but not limited to highly emetogenic chemotherapy, in the U.S.

AKYNZEO is a new oral fixed combination that targets two critical signaling

